Price Alert

Lexicon Pharmaceuticals I... (LXRX)

NASDAQ: LXRX · Real-Time Price · USD

1.20

0.02 (1.69%)

At close: Aug 15, 2025, 12:51 PM

1.69% (1D)

Bid	1.19
Market Cap	436.08M
Revenue (ttm)	58.43M
Net Income (ttm)	-120.62M
EPS (ttm)	-0.32
PE Ratio (ttm)	-3.75
Forward PE	-3.87
Analyst	Buy

Ask	1.2
Volume	1,676,639
Avg. Volume (20D)	4,002,620
Open	1.20
Previous Close	1.18
Day's Range	1.16 - 1.23
52-Week Range	0.28 - 2.17
Beta	1.18

About LXRX

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol LXRX

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for LXRX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Lexicon Pharmaceuticals has released their quartely earnings on Aug 6, 2025:

Revenue of $28.87M exceeds estimates by $23.35M, with 1652.64% YoY growth.

EPS of 0.01 exceeds estimates by 0.09, with 105.88% YoY growth.

Next Earnings Release

Lexicon Pharmaceuticals Inc. is scheduled to release its earnings on Nov 11, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 week ago

+9.52%

LXRX stock has given up its prior loss. Lexicon Ph... Unlock content with Pro Subscription

1 week ago

+9.52%

Lexicon Pharmaceuticals shares are trading lower following the release of its Q2 financial results.

News

1 week ago · zacks.com

Lexicon (LXRX) Upgraded to Buy: Here's What You Should Know

Lexicon (LXRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

1 week ago · fool.com

Lexicon (LXRX) Q2 Revenue Soars 1,706%

1 week ago · seekingalpha.com

Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2025 Earnings Call Transcript

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX ) Q2 2025 Earnings Conference Call August 6, 2025 8:30 AM ET Company Participants Craig B. Granowitz - Senior VP & Chief Medical Officer Lisa M.

1 week ago · zacks.com

Lexicon Pharmaceuticals (LXRX) Q2 Earnings and Revenues Top Estimates

Lexicon Pharmaceuticals (LXRX) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.08 per share. This compares to a loss of $0.17 per share a year...